Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
3.2 Mental state: Overall - clinically important change in overall mental state (>/= 50% reduction in PANSS endpoint score). Subgroup analyses: First episode schizophrenia	5	599	Risk Ratio (IV, Random, 95% CI)	0.75 [0.59, 0.96]
3.2.1 short term	4	397	Risk Ratio (IV, Random, 95% CI)	0.87 [0.70, 1.09]
3.2.2 medium term	1	202	Risk Ratio (IV, Random, 95% CI)	0.55 [0.41, 0.73]
3.3 Adverse effects/events: Specific - metabolic - weight increase. Subgroup analyses: First episode schizophrenia	4	566	Risk Ratio (IV, Random, 95% CI)	0.41 [0.27, 0.64]
3.3.1 increase - short term	2	329	Risk Ratio (IV, Random, 95% CI)	0.36 [0.26, 0.48]
3.3.2 increase - medium term	1	126	Risk Ratio (IV, Random, 95% CI)	0.63 [0.47, 0.84]
3.3.3 increase - long term	1	111	Risk Ratio (IV, Random, 95% CI)	0.14 [0.02, 1.10]
3.4 Leaving the study early: Adverse effects. Subgroup analyses: First episode schizophrenia	4	628	Risk Ratio (IV, Random, 95% CI)	2.30 [1.36, 3.89]
3.4.1 short term	1	263	Risk Ratio (IV, Random, 95% CI)	2.23 [0.71, 7.07]
3.4.2 medium term	2	254	Risk Ratio (IV, Random, 95% CI)	2.08 [0.86, 5.05]
3.4.3 long term	1	111	Risk Ratio (IV, Random, 95% CI)	2.53 [1.15, 5.56]

Comparison 4

COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
4.1 Global state: 1a. Average endpoint score (CGI, high=poor)	12		Mean Difference (IV, Random, 95% CI)	Subtotals only
4.1.1 total - short term	8	2639	Mean Difference (IV, Random, 95% CI)	0.25 [0.05, 0.45]
4.1.2 severity - short term	2	123	Mean Difference (IV, Random, 95% CI)	0.25 [-0.27, 0.78]
4.1.3 severity - medium term	2	315	Mean Difference (IV, Random, 95% CI)	0.09 [-0.18, 0.37]
4.1.4 improvement - short term	1	60	Mean Difference (IV, Random, 95% CI)	0.00 [-0.51, 0.51]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
4.1.5 improvement - medium term	1	254	Mean Difference (IV, Random, 95% CI)	0.10 [-0.24, 0.44]
4.2 Global state: 1b. Average endpoint score (CGI-S, high=poor, skewed data)	0		Other data	No numeric data
4.3 Mental state: 1a. Overall - clinically important change in overall mental state (>/= 20% reduction in PANSS endpoint score)	2	517	Risk Ratio (IV, Random, 95% CI)	0.88 [0.73, 1.07]
4.3.1 medium term	1	261	Risk Ratio (IV, Random, 95% CI)	0.85 [0.67, 1.07]
4.3.2 long term	1	256	Risk Ratio (IV, Random, 95% CI)	0.96 [0.69, 1.33]
4.4 Mental state: 1b. Overall - clinically important change in overall mental state - short term (>/= 25% reduction in PANSS endpoint score)	12	1008	Risk Ratio (IV, Random, 95% CI)	1.06 [0.85, 1.32]
4.5 Mental state: 1c. Overall - clinically important change in overall mental state - short term (>/= 75% reduction in PANSS endpoint score)	8	668	Risk Ratio (IV, Random, 95% CI)	0.73 [0.58, 0.90]
4.6 Mental state: 1d. Overall - clinically important change in overall mental state - short term (>/=40% reduction in BPRS endpoint score)	3	2335	Risk Ratio (IV, Random, 95% CI)	0.80 [0.62, 1.02]
4.7 Mental state: 1e. Overall - clinically important change in overall mental state-remission-medium term (PANSS score <=3 per symptom at least for 6 months)	2	316	Risk Ratio (IV, Random, 95% CI)	0.56 [0.31, 1.01]
4.8 Mental state: 2a. Overall - average endpoint score (PANSS total, high=poor)	35	5019	Mean Difference (IV, Random, 95% CI)	5.82 [4.18, 7.45]
4.8.1 short term	22	3765	Mean Difference (IV, Random, 95% CI)	5.02 [3.21, 6.82]
4.8.2 medium term	12	1210	Mean Difference (IV, Random, 95% CI)	7.27 [3.86, 10.67]
4.8.3 long term	1	44	Mean Difference (IV, Random, 95% CI)	7.32 [-3.99, 18.63]
4.9 Mental state: 2b. Overall - average endpoint score (BPRS total, high=poor)	6	417	Mean Difference (IV, Random, 95% CI)	1.02 [-0.57, 2.61]
4.9.1 short term	5	356	Mean Difference (IV, Random, 95% CI)	0.91 [-0.85, 2.67]
4.9.2 medium term	1	61	Mean Difference (IV, Random, 95% CI)	1.50 [-2.21, 5.21]
4.10 Mental state: 2c. Overall - average endpoint score (BPRS total, high=poor, skewed data)	0		Other data	No numeric data
4.11 Mental state: 3a. Overall - average change score - short	2	302	Mean Difference	9.24 [3.17, 15.31]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
term (PANSS total, high=poor)			(IV, Random, 95% CI)	
4.12 Mental state: 3b. Overall - average change score - short term (PANSS total, high=poor, skewed data)	0		Other data	No numeric data
4.13 Mental state: 4a. Specific - average endpoint score - depression - short term (MADRS , high=poor)	1	20	Mean Difference (IV, Random, 95% CI)	7.00 [4.76, 9.24]
4.14 Mental state: 4b. Specific - average endpoint score - depression (MADRS, high=poor, skewed data)	7		Other data	No numeric data
4.14.1 short term	6		Other data	No numeric data
4.14.3 long term change score	1		Other data	No numeric data
4.15 Mental state: 4c. Specific - average endpoint score - aggression - short term (MOAS, high=poor, skewed data)	1		Other data	No numeric data
4.15.1 Total score	1		Other data	No numeric data
4.15.2 Mean change total score	1		Other data	No numeric data
4.15.3 Change in Physical agression score	1		Other data	No numeric data
4.15.4 Physical aggression score	1		Other data	No numeric data
4.15.5 Aggression against property	1		Other data	No numeric data
4.15.6 Verbal aggression score	1		Other data	No numeric data
4.16 Mental state: 4d. Specific - average endpoint score - depression (various scales, high=poor, skewed data)	4		Other data	No numeric data
4.16.1 medium term (CDSS)	2		Other data	No numeric data
4.16.2 long term (CDSS)	1		Other data	No numeric data
4.16.3 short term (HAM-DRS)	2		Other data	No numeric data
4.16.4 medium term (HAM-DRS)	1		Other data	No numeric data
4.17 Mental state: 5a. Specific - negative symptoms - clinically important change(>/=20% reduction in PANSS-N)	2	309	Risk Ratio (IV, Random, 95% CI)	0.88 [0.71, 1.09]
4.17.1 short term	1	35	Risk Ratio (IV, Random, 95% CI)	0.72 [0.30, 1.71]
4.17.2 medium term	1	274	Risk Ratio (IV, Random, 95% CI)	0.89 [0.72, 1.11]
4.18 Mental state: 5b. Specific - negative symptoms - clinically important change - short term (>/=40% reduction in PANSS-N)	1	35	Risk Ratio (IV, Random, 95% CI)	0.51 [0.14, 1.79]
4.19 Mental state: 5c. Specific - negative symptoms - average endpoint score (PANSS-N, high=poor)	18	3474	Mean Difference (IV, Random, 95% CI)	2.01 [1.22, 2.80]
4.19.1 short term	16	3181	Mean Difference (IV, Random, 95% CI)	2.06 [1.25, 2.87]
4.19.2 medium term	1	249	Mean Difference (IV, Random, 95% CI)	0.30 [-1.20, 1.80]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
4.19.3 long term	1	44	Mean Difference (IV, Random, 95% CI)	4.75 [1.40, 8.10]
4.20 Mental state: 5d. Specific - negative symptoms - average endpoint score (PANSS-N, SANS scales, SMD, high=poor)	20	3649	Std. Mean Difference (IV, Random, 95% CI)	0.30 [0.17, 0.42]
4.20.1 short term	17	3244	Std. Mean Difference (IV, Random, 95% CI)	0.32 [0.18, 0.46]
4.20.2 medium term	2	310	Std. Mean Difference (IV, Random, 95% CI)	0.09 [-0.13, 0.32]
4.20.3 long term	2	95	Std. Mean Difference (IV, Random, 95% CI)	0.40 [-0.38, 1.19]
4.21 Mental state: 5e. Specific - negative symptoms - average endpoint score (various scales, high=poor, skewed data)	5		Other data	No numeric data
4.21.1 BPRS - short term	3		Other data	No numeric data
4.21.2 PANSS-N - short term	1		Other data	No numeric data
4.21.3 SANS - short term	2		Other data	No numeric data
4.21.4 SANS - medium term	1		Other data	No numeric data
4.21.5 SANS - long term	1		Other data	No numeric data
4.22 Mental state: 5f. Specific - negative symptoms - average change scores - long term (PANSS-N, high=poor, skewed data)	0		Other data	No numeric data
4.23 Mental state: 6a. Specific - positive symptoms - clinically important change - medium term (>/= 20% reduction in PANSS-P)	2	294	Risk Ratio (IV, Random, 95% CI)	1.01 [0.85, 1.20]
4.24 Mental state: 6b. Specific - positive symptoms - average endpoint score (PANSS-P, high=poor)	23	4027	Mean Difference (IV, Random, 95% CI)	1.03 [0.50, 1.55]
4.24.1 short term	20	3614	Mean Difference (IV, Random, 95% CI)	1.12 [0.53, 1.70]
4.24.2 medium term	2	369	Mean Difference (IV, Random, 95% CI)	0.33 [-0.88, 1.54]
4.24.3 long term	1	44	Mean Difference (IV, Random, 95% CI)	0.26 [-2.90, 3.42]
4.25 Mental state: 6c. Specific - positive symptoms - average endpoint score (PANSS-P, BPRS-P, SMD, high=poor)	24	4056	Std. Mean Difference (IV, Random, 95% CI)	0.20 [0.09, 0.31]
4.25.1 short term (PANSS-P, BPRS-P scales)	21	3643	Std. Mean Difference (IV, Random, 95% CI)	0.22 [0.10, 0.35]
4.25.2 medium term (PANSS-P only)	2	369	Std. Mean Difference (IV, Random, 95% CI)	0.06 [-0.15, 0.26]
4.25.3 long term (PANSS-P only)	1	44	Std. Mean Difference	0.05 [-0.54, 0.64]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
			(IV, Random, 95% CI)	
4.26 Mental state: 6d. Specific - positive symptoms - average endpoint score (various scales, high=poor, skewed data)	7		Other data	No numeric data
4.26.1 short term (BPRS)	4		Other data	No numeric data
4.26.2 short term (PANSS-P)	2		Other data	No numeric data
4.26.3 medium term (SAPS)	1		Other data	No numeric data
4.26.4 long term (SAPS)	1		Other data	No numeric data
4.27 Mental state: 6e. Specific - positive symptoms - average change score (PANSS-P, high=poor, skewed data)	3		Other data	No numeric data
4.27.1 short term	2		Other data	No numeric data
4.27.2 long term	1		Other data	No numeric data
4.28 Mental state: 7. Specific - psychopathology, general - average endpoint score (PANSS psychopathology, high=poor)	16	3370	Mean Difference (IV, Random, 95% CI)	1.59 [0.67, 2.52]
4.28.1 short term	14	3001	Mean Difference (IV, Random, 95% CI)	1.74 [0.73, 2.75]
4.28.2 medium term	2	369	Mean Difference (IV, Random, 95% CI)	0.46 [-1.59, 2.50]
4.29 Mental state: 8. Specific - various - average endpoint score - short term (PANSS subscales, high=poor)	4		Mean Difference (IV, Random, 95% CI)	Subtotals only
4.29.1 anxiety-depression	2	167	Mean Difference (IV, Random, 95% CI)	1.04 [-2.40, 4.48]
4.29.2 cognitive function	2	167	Mean Difference (IV, Random, 95% CI)	3.39 [-0.40, 7.19]
4.29.3 excitability	3	283	Mean Difference (IV, Random, 95% CI)	0.95 [0.18, 1.73]
4.29.4 excitation and agitation	1	60	Mean Difference (IV, Random, 95% CI)	1.20 [-0.53, 2.93]
4.30 Mental state: 9. Specific - time to onset of effect - short term	3	240	Mean Difference (IV, Random, 95% CI)	0.68 [-1.23, 2.59]
4.31 Mental state: 10. Specific - Needing additional benzodiazepines	6	3030	Risk Ratio (IV, Random, 95% CI)	1.10 [1.04, 1.17]
4.31.1 short term	6	2924	Risk Ratio (IV, Random, 95% CI)	1.10 [1.04, 1.17]
4.31.2 medium term	1	106	Risk Ratio (IV, Random, 95% CI)	0.35 [0.04, 3.22]
4.32 Functioning: 1a. General - average endpoint score - short term (GAF, high=good)	1	54	Mean Difference (IV, Random, 95% CI)	0.00 [-3.09, 3.09]
4.33 Functioning: 1b. General - average endpoint score - medium term (GAF, high=good, skewed data)	0		Other data	No numeric data

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
4.34 Functioning: 2a. Specific - cognition-average endpoint score - long term (SCD, high=poor)	1	240	Mean Difference (IV, Random, 95% CI)	0.60 [-0.60, 1.80]
4.35 Functioning: 2b. Specific - cognition - average endpoint scores - short term (various domains, high=good)	1		Mean Difference (IV, Random, 95% CI)	Subtotals only
4.35.1 neuro-cognition - California Verbal Learning Test	1	60	Mean Difference (IV, Random, 95% CI)	4.60 [-1.91, 11.11]
4.35.2 neuro-cognition - Controlled Oral Word Association Test	1	60	Mean Difference (IV, Random, 95% CI)	7.20 [0.57, 13.83]
4.35.3 neuro-cognition - Degraded Stimulus Continuous Performance Test	1	60	Mean Difference (IV, Random, 95% CI)	0.05 [-0.01, 0.11]
4.35.4 neuro-cognition - Digit Symbol coding	1	60	Mean Difference (IV, Random, 95% CI)	2.60 [-4.01, 9.21]
4.35.5 neuro-cognition - Grooved Pegboard Test	1	60	Mean Difference (IV, Random, 95% CI)	-14.80 [-42.36, 12.76]
4.35.6 neuro-cognition - Letter Number Span	1	60	Mean Difference (IV, Random, 95% CI)	2.80 [0.35, 5.25]
4.35.7 neuro-cognition - Wisconsin Card Sorting Test	1	60	Mean Difference (IV, Random, 95% CI)	0.80 [-0.15, 1.75]
4.35.8 social cognition - Facial Emotion Identification Test	1	60	Mean Difference (IV, Random, 95% CI)	-0.50 [-2.11, 1.11]
4.35.9 social cognition - Half Profile of Nonverbal Sensitivity	1	60	Mean Difference (IV, Random, 95% CI)	1.80 [-2.67, 6.27]
4.35.10 social cognition - Interpersonal Perception Task	1	60	Mean Difference (IV, Random, 95% CI)	0.80 [-0.03, 1.63]
4.35.11 social cognition - Voice Emotion Identification Test	1	60	Mean Difference (IV, Random, 95% CI)	0.20 [-1.76, 2.16]
4.36 Functioning: 2c. Specific - cognition - average endpoint scores - medium term (various domains, high=good)	1		Mean Difference (IV, Random, 95% CI)	Subtotals only
4.36.1 attention	1	24	Mean Difference (IV, Random, 95% CI)	-1.78 [-10.93, 7.37]
4.36.2 functions - executive	1	28	Mean Difference (IV, Random, 95% CI)	18.09 [-14.33, 50.51]
4.36.3 processing speed	1	28	Mean Difference (IV, Random, 95% CI)	0.21 [-2.15, 2.57]
4.36.4 memory - visual	1	27	Mean Difference (IV, Random, 95% CI)	3.42 [-3.27, 10.11]
4.36.5 memory - working	1	28	Mean Difference (IV, Random, 95% CI)	-0.60 [-1.86, 0.66]
4.36.6 neuro-cognition - Grooved Pegboard Test	1	48	Mean Difference (IV, Random, 95% CI)	4.37 [-1.08, 9.82]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
4.36.7 neuro-cognition - Rey Auditory Verbal Learning	1	61	Mean Difference (IV, Random, 95% CI)	-3.09 [-8.90, 2.72]
4.36.8 neuro-cognition - Brief Test of Attention	1	49	Mean Difference (IV, Random, 95% CI)	-0.76 [-2.45, 0.93]
4.36.9 neuro-cognition - Finger Tapping Test	1	47	Mean Difference (IV, Random, 95% CI)	0.27 [-5.00, 5.54]
4.36.10 neuro-cognition -FAS verbal fluency test	1	60	Mean Difference (IV, Random, 95% CI)	-5.86 [-11.24, -0.48]
4.37 Functioning: 2d. Specific - cognition - average change scores - medium term (various domains, high=good, skewed data)	3		Other data	No numeric data
4.37.1 Composite score	1		Other data	No numeric data
4.37.2 Global Cognitive Index	2		Other data	No numeric data
4.37.3 Purdue Pegboard Test	1		Other data	No numeric data
4.37.4 Rey Auditory Verbal Learning Test	1		Other data	No numeric data
4.37.5 Trail Making Test part A	1		Other data	No numeric data
4.37.6 Trail Making Test part B	1		Other data	No numeric data
4.37.7 WAIS III digit symbol	1		Other data	No numeric data
4.38 Adverse effects/events: 1a. General - at least one event or effect - short term (various scales)	1	182	Risk Ratio (IV, Random, 95% CI)	1.10 [0.89, 1.36]
4.39 Adverse effects/events: 1b. General - severe enough to cause withdrawal from study	12	1967	Risk Ratio (IV, Random, 95% CI)	2.10 [1.52, 2.90]
4.39.1 short term	5	800	Risk Ratio (IV, Random, 95% CI)	3.63 [1.76, 7.48]
4.39.2 medium term	5	800	Risk Ratio (IV, Random, 95% CI)	1.77 [1.07, 2.94]
4.39.3 long term	2	367	Risk Ratio (IV, Random, 95% CI)	1.90 [1.13, 3.18]
4.40 Adverse effects/events: 2a. General - needing additional medication - short term	7		Risk Ratio (IV, Random, 95% CI)	Subtotals only
4.40.1 needing some anticholinergic drugs	6	3326	Risk Ratio (IV, Random, 95% CI)	3.47 [2.50, 4.83]
4.40.2 needing benzodiazepines	4	2394	Risk Ratio (IV, Random, 95% CI)	1.10 [1.02, 1.17]
4.40.3 needing propranolol	1	263	Risk Ratio (IV, Random, 95% CI)	8.06 [2.49, 26.12]
4.41 Adverse effects/events: 2b. General - needing additional medication - medium term	1		Risk Ratio (IV, Random, 95% CI)	Subtotals only
4.41.1 needing benzodiazepines	1	106	Risk Ratio (IV, Random, 95% CI)	0.35 [0.04, 3.22]
4.42 Adverse effects/events: 2c General - needing additional medication - long term	2		Risk Ratio (IV, Random, 95% CI)	Subtotals only
4.42.1 needing anticholinergic drugs	2	314	Risk Ratio (IV, Random, 95% CI)	4.64 [0.48, 45.16]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
4.43 Adverse effects/events: 3b. Specific - extrapyramidal - various specific effects - short term	18		Risk Ratio (IV, Random, 95% CI)	Subtotals only
4.43.1 abnormal gait	1	182	Risk Ratio (IV, Random, 95% CI)	8.88 [2.11, 37.34]
4.43.2 akathisia	16	4038	Risk Ratio (IV, Random, 95% CI)	3.33 [2.79, 3.98]
4.43.3 bradykinesia	1	182	Risk Ratio (IV, Random, 95% CI)	8.88 [2.11, 37.34]
4.43.4 dyskinetic movements	3	2777	Risk Ratio (IV, Random, 95% CI)	2.71 [0.79, 9.28]
4.43.5 dystonia, acute	7	3160	Risk Ratio (IV, Random, 95% CI)	8.25 [3.53, 19.29]
4.43.6 hypertonia	6	2948	Risk Ratio (IV, Random, 95% CI)	4.47 [2.29, 8.69]
4.43.7 hypokinesia	2	2023	Risk Ratio (IV, Random, 95% CI)	2.34 [1.82, 3.01]
4.43.8 myotonia	3	256	Risk Ratio (IV, Random, 95% CI)	5.01 [2.42, 10.36]
4.43.9 parkinsonism	3	2286	Risk Ratio (IV, Random, 95% CI)	2.57 [2.02, 3.26]
4.43.10 rigidity	1	27	Risk Ratio (IV, Random, 95% CI)	6.80 [1.78, 25.92]
4.43.11 tremor	13	4002	Risk Ratio (IV, Random, 95% CI)	3.82 [2.56, 5.69]
4.44 Adverse effects/events: 3c. Specific - extrapyramidal - various specific effects - medium term	5		Risk Ratio (IV, Random, 95% CI)	Subtotals only
4.44.1 akathisia	5	853	Risk Ratio (IV, Random, 95% CI)	2.15 [1.42, 3.25]
4.44.2 dyskinetic movements	2	398	Risk Ratio (IV, Random, 95% CI)	1.67 [0.67, 4.14]
4.44.3 dystonia, acute	1	170	Risk Ratio (IV, Random, 95% CI)	3.97 [0.16, 96.14]
4.44.4 parkinsonism	2	313	Risk Ratio (IV, Random, 95% CI)	3.14 [1.05, 9.36]
4.44.5 dysarthria	1	71	Risk Ratio (IV, Random, 95% CI)	3.90 [0.19, 78.46]
4.44.6 tremor	1	274	Risk Ratio (IV, Random, 95% CI)	4.77 [1.05, 21.68]
4.45 Adverse effects/events: 3d. Specific - extrapyramidal - various specific effects - long term	2		Risk Ratio (IV, Random, 95% CI)	Subtotals only
4.45.1 akathisia	2	364	Risk Ratio (IV, Random, 95% CI)	2.92 [1.61, 5.30]
4.45.2 tremor	1	256	Risk Ratio (IV, Random, 95% CI)	1.64 [0.79, 3.39]
4.46 Adverse effects/events: 3e. Specific - extrapyramidal - average endpoint score - medium term (BAS total, high=poor)	1	71	Mean Difference (IV, Random, 95% CI)	22.75 [20.10, 25.40]
4.47 Adverse effects/events: 3f. Specific -	1	71	Mean Difference	16.00 [14.00, 18.00]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
extrapyramidal - average endpoint score - medium term (SAS total, high=poor)			(IV, Random, 95% CI)	
4.48 Adverse effects/events: 3g. Specific - extrapyramidal - average endpoint score (BAS, high=poor, skewed data)	6		Other data	No numeric data
4.48.1 akathisia - short term	4		Other data	No numeric data
4.48.2 total score - medium term	1		Other data	No numeric data
4.48.3 total score - long term	1		Other data	No numeric data
4.48.4 total - endpoint change score- long term	1		Other data	No numeric data
4.49 Adverse effects/events: 3h. Specific - extrapyramidal - average endpoint score (SAS, high=poor, skewed data)	10		Other data	No numeric data
4.49.1 parkinsonism - short term	4		Other data	No numeric data
4.49.2 total - short term	3		Other data	No numeric data
4.49.3 total - medium term	2		Other data	No numeric data
4.49.4 total - long term	1		Other data	No numeric data
4.49.5 total- endpoint change- long term	1		Other data	No numeric data
4.50 Adverse effects/events: 3i. Specific - extrapyramidal - average endpoint score - short term (AIMS, high=poor, skewed data)	4		Other data	No numeric data
4.50.1 dyskinesia	2		Other data	No numeric data
4.50.2 total	1		Other data	No numeric data
4.50.3 AIMS total - endpoint change - long term	1		Other data	No numeric data
4.51 Adverse effects/events: 3j. Specific - extrapyramidal - average endpoint score - short term (DIEPSS, high=poor, skewed data)	1		Other data	No numeric data
4.51.1 akathisia	1		Other data	No numeric data
4.51.2 dyskinesia	1		Other data	No numeric data
4.51.3 dystonia	1		Other data	No numeric data
4.51.4 overall severity	1		Other data	No numeric data
4.51.5 parkinsonism	1		Other data	No numeric data
4.51.6 total score	1		Other data	No numeric data
4.52 Adverse effects/events: 3k. Specific - extrapyramidal - average endpoint score (ESRS, high score=poor, skewed data)	4		Other data	No numeric data
4.52.1 ESRS total - short term	1		Other data	No numeric data
4.52.2 parkinsonism - short term	2		Other data	No numeric data
4.52.3 parkinsonism, dyskinesia, dystonia (subjective) - short term	1		Other data	No numeric data
4.52.4 parkinsonism - long term	1		Other data	No numeric data
4.53 Adverse effects/events: 4b. Specific - metabolic - weight decrease	2	456	Risk Ratio (IV, Random, 95% CI)	5.64 [1.26, 25.36]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
4.53.1 decrease - short term	1	182	Risk Ratio (IV, Random, 95% CI)	7.31 [0.92, 58.26]
4.53.2 decrease- medium term	1	274	Risk Ratio (IV, Random, 95% CI)	4.24 [0.48, 37.46]
4.54 Adverse effects/events: 4c. Specific - metabolic - weight - high BMI (>=25kg/m2) - medium term	2	172	Risk Ratio (IV, Random, 95% CI)	1.07 [0.37, 3.09]
4.55 Adverse effects/events: 4d. Specific - metabolic - weight - average endpoint (kg)	11	2640	Mean Difference (IV, Random, 95% CI)	-0.62 [-1.92, 0.68]
4.55.1 short term	7	2478	Mean Difference (IV, Random, 95% CI)	-0.29 [-1.65, 1.07]
4.55.2 medium term	3	115	Mean Difference (IV, Random, 95% CI)	-4.25 [-10.68, 2.18]
4.55.3 long term	1	47	Mean Difference (IV, Random, 95% CI)	-0.96 [-12.45, 10.53]
4.56 Adverse effects/events: 4e. Specific - metabolic - weight - average increase - short term	2	283	Mean Difference (IV, Random, 95% CI)	-3.53 [-5.79, -1.28]
4.57 Adverse effects/events: 4f. Specific - metabolic - weight - waist circumference at endpoint - short term (high=poor)	1	66	Mean Difference (IV, Random, 95% CI)	-5.00 [-8.73, -1.27]
4.58 Adverse effects/events: 4g. Specific - metabolic - weight - waist circumference change data- medium term (high=poor, skewed data)	0		Other data	No numeric data
4.59 Adverse effects/events: 4h. Specific - metabolic - weight - average change various measures (skewed data)	6		Other data	No numeric data
4.59.1 BMI - short term	2		Other data	No numeric data
4.59.2 BMI - medium term	1		Other data	No numeric data
4.59.3 weight gain (kg) - short term	1		Other data	No numeric data
4.59.4 weight gain (kg) - medium term	3		Other data	No numeric data
4.59.5 weight gain (kg) - lomg term	1		Other data	No numeric data
4.60 Adverse effects/events: 5a. Specific - metabolic - metabolism-related final serum levels (various measures)	6		Risk Ratio (IV, Random, 95% CI)	Subtotals only
4.60.1 cholesterol - high - short term	1	34	Risk Ratio (IV, Random, 95% CI)	0.18 [0.01, 3.47]
4.60.2 cholesterol - high - medium term	3	419	Risk Ratio (IV, Random, 95% CI)	0.92 [0.63, 1.35]
4.60.3 glucose - high - short term	3	464	Risk Ratio (IV, Random, 95% CI)	0.20 [0.01, 3.93]
4.60.4 glucose - high - medium term	3	416	Risk Ratio (IV, Random, 95% CI)	1.09 [0.44, 2.72]
4.60.5 HDL - low - short term	2	163	Risk Ratio (IV, Random, 95% CI)	0.61 [0.30, 1.21]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
4.60.6 LDL - high - medium term	1	97	Risk Ratio (IV, Random, 95% CI)	0.97 [0.65, 1.47]
4.60.7 trygliceride - high - short term	2	100	Risk Ratio (IV, Random, 95% CI)	0.46 [0.18, 1.16]
4.60.8 trygliceride - high - medium term	3	419	Risk Ratio (IV, Random, 95% CI)	0.85 [0.56, 1.30]
4.61 Adverse effects/events: 5b. Specific - metabolic - metabolism-related serum levels (high=poor)	4		Mean Difference (IV, Random, 95% CI)	Subtotals only
4.61.1 lipids - HDL-C - short term	1	72	Mean Difference (IV, Random, 95% CI)	0.05 [-0.11, 0.21]
4.61.2 lipids - LDL-C - short term	1	72	Mean Difference (IV, Random, 95% CI)	-0.34 [-0.51, -0.17]
4.61.3 cholesterol, total - short term	1	35	Mean Difference (IV, Random, 95% CI)	21.10 [-6.88, 49.08]
4.61.4 cholesterol, total - medium term	1	34	Mean Difference (IV, Random, 95% CI)	-7.00 [-27.17, 13.17]
4.61.5 sugar - FBS - short term	1	66	Mean Difference (IV, Random, 95% CI)	-0.40 [-8.46, 7.66]
4.61.6 triglyceride - short term	3	173	Mean Difference (IV, Random, 95% CI)	-30.86 [-73.50, 11.78]
4.61.7 sugar - PPBS - short term	2	101	Mean Difference (IV, Random, 95% CI)	-12.23 [-19.95, -4.51]
4.61.8 triglyceride - medium term	1	34	Mean Difference (IV, Random, 95% CI)	-25.00 [-46.33, -3.67]
4.62 Adverse effects/events: 5c. Specific - metabolic - metabolism-related HDL serum levels - endpoint (high=poor)	2	100	Mean Difference (IV, Random, 95% CI)	3.76 [-11.81, 19.33]
4.62.1 short term	1	66	Mean Difference (IV, Random, 95% CI)	-3.90 [-9.33, 1.53]
4.62.2 medium term	1	34	Mean Difference (IV, Random, 95% CI)	12.00 [3.92, 20.08]
4.63 Adverse effects/events: 5d. Specific - metabolic - metabolism-related serum levels - average change (high=poor, skewed data)	4		Other data	No numeric data
4.63.1 cholesterol - short term	2		Other data	No numeric data
4.63.2 cholesterol - medium term	1		Other data	No numeric data
4.63.3 cholesterol - long term	1		Other data	No numeric data
4.63.4 glucose (mg/dl) - short term	1		Other data	No numeric data
4.63.5 glucose (mg/dl) - medium term	1		Other data	No numeric data
4.63.6 glucose (mg/dl) - long term	1		Other data	No numeric data
4.63.7 HDL - medium term	2		Other data	No numeric data
4.63.8 insulin (mU/ml) - medium term	1		Other data	No numeric data

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
4.63.9 LDL - medium term	2		Other data	No numeric data
4.63.10 triglyceride - short term	2		Other data	No numeric data
4.63.11 triglyceride - medium term	1		Other data	No numeric data
4.63.12 triglyceride - long term	1		Other data	No numeric data
4.63.13 prolactine - long term	1		Other data	No numeric data
4.64 Adverse effects/events: 6. Specific - metabolic - various binary - short term	3		Risk Ratio (IV, Random, 95% CI)	Subtotals only
4.64.1 metabolic syndrome	2	107	Risk Ratio (IV, Random, 95% CI)	0.40 [0.03, 5.30]
4.64.2 diabetes	1	66	Risk Ratio (IV, Random, 95% CI)	0.85 [0.21, 3.49]
4.64.3 metabolism and nutrition disorders, unspecified	1	48	Risk Ratio (IV, Random, 95% CI)	0.39 [0.04, 4.00]
4.65 Adverse effects/events: 7a. Specific - anticholinergic - various - short term	16		Risk Ratio (IV, Random, 95% CI)	Subtotals only
4.65.1 blurred vision	8	2475	Risk Ratio (IV, Random, 95% CI)	1.70 [0.99, 2.93]
4.65.2 constipation	9	633	Risk Ratio (IV, Random, 95% CI)	1.86 [1.18, 2.95]
4.65.3 salivation - too little	12	3002	Risk Ratio (IV, Random, 95% CI)	1.19 [0.74, 1.92]
4.65.4 salivation - too much	6	2816	Risk Ratio (IV, Random, 95% CI)	3.67 [1.81, 7.42]
4.65.5 headache	2	154	Risk Ratio (IV, Random, 95% CI)	1.97 [0.89, 4.36]
4.65.6 nervousess	1	100	Risk Ratio (IV, Random, 95% CI)	2.17 [0.70, 6.74]
4.65.7 urination difficulties	2	2023	Risk Ratio (IV, Random, 95% CI)	2.02 [0.95, 4.29]
4.65.8 hypotension	4	340	Risk Ratio (IV, Random, 95% CI)	1.92 [0.56, 6.66]
4.65.9 perspiration	3	2122	Risk Ratio (IV, Random, 95% CI)	1.96 [1.49, 2.60]
4.66 Adverse effects/events: 7b. Specific - anticholinergic - various - medium term	1		Risk Ratio (IV, Random, 95% CI)	Subtotals only
4.66.1 dysarthria	1	71	Risk Ratio (IV, Random, 95% CI)	3.90 [0.19, 78.46]
4.66.2 urination difficulties	1	71	Risk Ratio (IV, Random, 95% CI)	3.90 [0.19, 78.46]
4.66.3 rash	1	71	Risk Ratio (IV, Random, 95% CI)	0.16 [0.01, 3.14]
4.66.4 anemia	1	71	Risk Ratio (IV, Random, 95% CI)	3.90 [0.19, 78.46]
4.67 Adverse effects/events: 7c. Specific - anticholinergic - various - long term	2		Risk Ratio (IV, Random, 95% CI)	Subtotals only
4.67.1 salivation - too little	2	367	Risk Ratio (IV, Random, 95% CI)	0.88 [0.32, 2.46]
4.67.2 dizziness	1	256	Risk Ratio (IV, Random, 95% CI)	1.75 [0.91, 3.37]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
4.67.3 paranoid reaction	1	256	Risk Ratio (IV, Random, 95% CI)	1.64 [0.71, 3.79]
4.67.4 abnormal thinking	1	256	Risk Ratio (IV, Random, 95% CI)	0.98 [0.37, 2.62]
4.67.5 constipation	1	256	Risk Ratio (IV, Random, 95% CI)	1.64 [0.54, 4.94]
4.67.6 headache	1	256	Risk Ratio (IV, Random, 95% CI)	1.21 [0.72, 2.04]
4.67.7 nervousness	1	256	Risk Ratio (IV, Random, 95% CI)	1.55 [0.84, 2.86]
4.68 Adverse effects/events: 8a. Specific - arousal - various [non-sleep] measures	9		Risk Ratio (IV, Random, 95% CI)	Subtotals only
4.68.1 agitation - short term	3	421	Risk Ratio (IV, Random, 95% CI)	1.35 [0.73, 2.51]
4.68.2 agitation - medium term	1	274	Risk Ratio (IV, Random, 95% CI)	0.27 [0.03, 2.34]
4.68.3 agitation - long term	1	256	Risk Ratio (IV, Random, 95% CI)	1.87 [0.70, 5.00]
4.68.4 anxiety - short term	2	282	Risk Ratio (IV, Random, 95% CI)	0.86 [0.25, 2.94]
4.68.5 anxiety - medium term	2	345	Risk Ratio (IV, Random, 95% CI)	1.85 [1.10, 3.10]
4.68.6 anxiety - long term	1	256	Risk Ratio (IV, Random, 95% CI)	0.64 [0.34, 1.23]
4.68.7 excitement - short term	1	182	Risk Ratio (IV, Random, 95% CI)	1.04 [0.56, 1.96]
4.68.8 hostility - short term	1	267	Risk Ratio (IV, Random, 95% CI)	0.61 [0.27, 1.42]
4.68.9 slow response - short term	1	100	Risk Ratio (IV, Random, 95% CI)	5.00 [1.15, 21.67]
4.68.10 withdrawal - short term	1	267	Risk Ratio (IV, Random, 95% CI)	1.72 [0.97, 3.07]
4.68.11 concentration difficulty - medium term	1	111	Risk Ratio (IV, Random, 95% CI)	0.49 [0.05, 5.26]
4.68.12 delusions - medium term	1	274	Risk Ratio (IV, Random, 95% CI)	0.67 [0.27, 1.69]
4.68.13 suicide attempt-medium term	1	274	Risk Ratio (IV, Random, 95% CI)	0.85 [0.23, 3.09]
4.68.14 hallucinations-medium term	1	272	Risk Ratio (IV, Random, 95% CI)	0.27 [0.03, 2.38]
4.68.15 hallucinations-long term	1	256	Risk Ratio (IV, Random, 95% CI)	1.00 [0.49, 2.03]
4.68.16 depression - long term	1	256	Risk Ratio (IV, Random, 95% CI)	0.64 [0.34, 1.23]
4.68.17 pain - long term	1	256	Risk Ratio (IV, Random, 95% CI)	0.57 [0.25, 1.31]
4.68.18 rhinitis - long term	1	256	Risk Ratio (IV, Random, 95% CI)	1.64 [0.91, 2.94]
4.69 Adverse effects/events: 8b. Specific - arousal - sleep/sleepiness - various binary outcomes	19		Risk Ratio (IV, Random, 95% CI)	Subtotals only
4.69.1 drowsiness - short term	11	3064	Risk Ratio (IV, Random, 95% CI)	1.07 [0.84, 1.37]
4.69.2 drowsiness - daytime - long term	1	111	Risk Ratio (IV, Random,	0.05 [0.00, 0.87]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
			95% CI)	
4.69.3 sedation - short term	1	20	Risk Ratio (IV, Random, 95% CI)	0.25 [0.03, 1.86]
4.69.4 sleep - difficulty in getting to sleep - short term	7	3124	Risk Ratio (IV, Random, 95% CI)	1.15 [0.76, 1.73]
4.69.5 sleep - insomnia - medium term	1	274	Risk Ratio (IV, Random, 95% CI)	1.41 [0.50, 3.97]
4.69.6 sleep - increased hours - long term	1	111	Risk Ratio (IV, Random, 95% CI)	0.33 [0.04, 3.05]
4.69.7 somnolence - long term	2	367	Risk Ratio (IV, Random, 95% CI)	0.18 [0.01, 4.58]
4.69.8 somnolence- medium term	1	274	Risk Ratio (IV, Random, 95% CI)	0.71 [0.12, 4.16]
4.69.9 insomnia - short term	1	100	Risk Ratio (IV, Random, 95% CI)	2.17 [0.57, 8.19]
4.69.10 somnolence - short term	1	100	Risk Ratio (IV, Random, 95% CI)	1.44 [0.67, 3.12]
4.69.11 insomnia - long term	1	256	Risk Ratio (IV, Random, 95% CI)	1.26 [0.75, 2.13]
4.70 Adverse effects/events: 9a. Specific - cardiovascular - various binary measures	19		Risk Ratio (IV, Random, 95% CI)	Subtotals only
4.70.1 cardiac disorders - unspecified - short term	1	48	Risk Ratio (IV, Random, 95% CI)	0.26 [0.01, 6.12]
4.70.2 cardiovascular - palpitations - short term	5	2312	Risk Ratio (IV, Random, 95% CI)	1.31 [0.82, 2.09]
4.70.3 electrocardiogram abnormality - short term	4	372	Risk Ratio (IV, Random, 95% CI)	1.64 [0.52, 5.15]
4.70.4 hypotension - postural - short term	1	120	Risk Ratio (IV, Random, 95% CI)	1.00 [0.21, 4.76]
4.70.5 QTc interval prolongation >0.5s - short term	2	398	Risk Ratio (IV, Random, 95% CI)	0.08 [0.02, 0.42]
4.70.6 QTc interval prolongation >0.5s - medium term	1	62	Risk Ratio (IV, Random, 95% CI)	0.75 [0.08, 6.79]
4.70.7 cardiovascular - dizziness - short term	7	761	Risk Ratio (IV, Random, 95% CI)	1.13 [0.53, 2.37]
4.70.8 blood hypertension - medium term	1	71	Risk Ratio (IV, Random, 95% CI)	0.78 [0.12, 5.20]
4.70.9 cardiovascular - bradichardia - medium term	1	71	Risk Ratio (IV, Random, 95% CI)	3.90 [0.19, 78.46]
4.70.10 blood hypertension - short term	1	66	Risk Ratio (IV, Random, 95% CI)	0.05 [0.01, 0.38]
4.70.11 myocardial tiredness - short term	2	160	Risk Ratio (IV, Random, 95% CI)	3.00 [1.01, 8.91]
4.70.12 nodal tachycardia - short term	2	152	Risk Ratio (IV, Random, 95% CI)	1.13 [0.23, 5.48]
4.71 Adverse effects/events: 9b. Specific - cardiovascular - blood pressure endpoint - short term (high=poor)	2		Mean Difference (IV, Random, 95% CI)	Subtotals only
4.71.1 systolic	2	126	Mean Difference (IV, Random, 95% CI)	-6.40 [-9.46, -3.34]
4.71.2 diastolic	2	126	Mean Difference (IV, Random, 95% CI)	-1.83 [-4.55, 0.89]
4.72 Adverse effects/events: 10a.	11		Risk Ratio (IV, Random,	Subtotals only

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
Specific - gastrointestinal			95% CI)	
4.72.1 anorexia - short term	3	362	Risk Ratio (IV, Random, 95% CI)	5.25 [2.68, 10.30]
4.72.2 appetite - increase- short term	1	1996	Risk Ratio (IV, Random, 95% CI)	0.61 [0.50, 0.74]
4.72.3 diarrhoea - short term	3	484	Risk Ratio (IV, Random, 95% CI)	0.52 [0.17, 1.66]
4.72.4 gastrointestinal disorders - unspecified - short term	1	48	Risk Ratio (IV, Random, 95% CI)	2.33 [0.26, 20.85]
4.72.5 sickness - nausea - short term	5	2601	Risk Ratio (IV, Random, 95% CI)	1.43 [0.83, 2.46]
4.72.6 nausea -medium term	1	274	Risk Ratio (IV, Random, 95% CI)	9.54 [0.52, 175.46]
4.72.7 nausea -long term	1	256	Risk Ratio (IV, Random, 95% CI)	0.89 [0.47, 1.66]
4.72.8 sickness - vomiting - short term	1	1996	Risk Ratio (IV, Random, 95% CI)	1.69 [1.28, 2.24]
4.72.9 diarrhoea - long term	1	256	Risk Ratio (IV, Random, 95% CI)	1.64 [0.84, 3.20]
4.72.10 vomiting - long term	1	256	Risk Ratio (IV, Random, 95% CI)	2.13 [0.97, 4.67]
4.73 Adverse effects/events: 10b. Specific - hepatic/haematological disfunction - short term	6	600	Risk Ratio (IV, Random, 95% CI)	2.21 [0.83, 5.93]
4.73.1 abnormal blood routine test	2	180	Risk Ratio (IV, Random, 95% CI)	4.00 [0.87, 18.31]
4.73.2 abnormal liver dysfunction	2	176	Risk Ratio (IV, Random, 95% CI)	0.91 [0.14, 6.07]
4.73.3 transaminase increase	2	176	Risk Ratio (IV, Random, 95% CI)	1.35 [0.10, 19.20]
4.73.4 SGPT increase	1	68	Risk Ratio (IV, Random, 95% CI)	5.00 [0.25, 100.43]
4.74 Adverse effects/events: 10c. Specific - hormonal - high prolactin levels	2	200	Risk Ratio (IV, Random, 95% CI)	0.97 [0.69, 1.36]
4.74.1 short term	1	70	Risk Ratio (IV, Random, 95% CI)	1.01 [0.61, 1.69]
4.74.2 medium term	2	130	Risk Ratio (IV, Random, 95% CI)	0.93 [0.59, 1.47]
4.75 Adverse effects/events: 10d. Specific - hormonal - serum levels - short term	1		Mean Difference (IV, Random, 95% CI)	Subtotals only
4.75.1 prolactin	1	61	Mean Difference (IV, Random, 95% CI)	80.65 [63.98, 97.32]
4.75.2 growth hormone	1	61	Mean Difference (IV, Random, 95% CI)	-0.44 [-1.19, 0.31]
4.76 Adverse effects/events: 11. Specific - renal - average creatinine change - short term (skewed data)	0		Other data	No numeric data
4.77 Adverse effects/events: 12. Specific - death - during study or within 30 days of study discontinuation	3	9459	Risk Ratio (IV, Random, 95% CI)	0.74 [0.31, 1.75]
4.77.1 all causes	2	2427	Risk Ratio (IV, Random,	0.54 [0.14, 2.05]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
			95% CI)	
4.77.2 suicide and accidental injury	3	2609	Risk Ratio (IV, Random, 95% CI)	0.78 [0.12, 5.20]
4.77.3 other causes	2	2427	Risk Ratio (IV, Random, 95% CI)	0.67 [0.07, 6.47]
4.77.4 unknown	1	1996	Risk Ratio (IV, Random, 95% CI)	6.07 [0.25, 148.75]
4.78 Adverse effects/events: 13. Specific - others	10		Risk Ratio (IV, Random, 95% CI)	Subtotals only
4.78.1 asthenia - short term	2	127	Risk Ratio (IV, Random, 95% CI)	1.67 [0.77, 3.64]
4.78.2 asthenia- medium term	1	274	Risk Ratio (IV, Random, 95% CI)	0.71 [0.12, 4.16]
4.78.3 asthenia - long term	1	111	Risk Ratio (IV, Random, 95% CI)	0.16 [0.02, 1.32]
4.78.4 depressive syndrome - medium term	1	71	Risk Ratio (IV, Random, 95% CI)	0.26 [0.03, 2.36]
4.78.5 dysphagia - short term	1	100	Risk Ratio (IV, Random, 95% CI)	3.00 [0.13, 71.92]
4.78.6 eye disorders, unspecified - short term	1	48	Risk Ratio (IV, Random, 95% CI)	0.26 [0.01, 6.12]
4.78.7 general diseases, unspecified - short term	1	48	Risk Ratio (IV, Random, 95% CI)	0.78 [0.05, 11.72]
4.78.8 malaise - short term	1	182	Risk Ratio (IV, Random, 95% CI)	1.04 [0.46, 2.39]
4.78.9 nervous system disorders, unspecified - short term	1	48	Risk Ratio (IV, Random, 95% CI)	1.36 [0.46, 4.04]
4.78.10 psychiatric disorders, unspecified - short term	1	48	Risk Ratio (IV, Random, 95% CI)	0.39 [0.14, 1.12]
4.78.11 rash - short term	1	20	Risk Ratio (IV, Random, 95% CI)	3.00 [0.14, 65.90]
4.78.12 rash - medium term	1	71	Risk Ratio (IV, Random, 95% CI)	0.16 [0.01, 3.14]
4.78.13 reproductive system and breast disorders, unspecified - short term	1	48	Risk Ratio (IV, Random, 95% CI)	0.16 [0.01, 3.11]
4.78.14 respiratory, thoracic, mediastinal disorders, unspecified - short term	1	48	Risk Ratio (IV, Random, 95% CI)	0.16 [0.01, 3.11]
4.78.15 skin and subcutaneous tissue disorders, unspecified - short term	1	48	Risk Ratio (IV, Random, 95% CI)	0.26 [0.01, 6.12]
4.78.16 torsion-spasm - short term	2	176	Risk Ratio (IV, Random, 95% CI)	0.94 [0.10, 9.25]
4.79 Quality of life: 2a. Specific - average endpoint score - short term (QLS-Heinrich&Carpenter, high=good)	2		Mean Difference (IV, Random, 95% CI)	Subtotals only
4.79.1 total	2	299	Mean Difference (IV, Random, 95% CI)	-2.89 [-7.88, 2.10]
4.79.2 interpersonal relations	1	245	Mean Difference (IV, Random, 95% CI)	-0.46 [-2.92, 2.00]
4.79.3 intrapsychic foundations	1	245	Mean Difference (IV, Random, 95% CI)	-0.58 [-2.57, 1.41]
4.79.4 common objects and activities	1	245	Mean Difference	-0.41 [-1.03, 0.21]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
			(IV, Random, 95% CI)	
4.79.5 instrumental role	1	245	Mean Difference (IV, Random, 95% CI)	-0.95 [-1.96, 0.06]
4.79.6 common objects and activities	1	245	Mean Difference (IV, Random, 95% CI)	-0.41 [-1.03, 0.21]
4.80 Quality of life: 2b. Specific - average endpoint score - short term (WHO-QOL-BREF, high=good)	2		Mean Difference (IV, Random, 95% CI)	Subtotals only
4.80.1 environment	2	314	Mean Difference (IV, Random, 95% CI)	2.40 [-4.64, 9.45]
4.80.2 physical health	2	314	Mean Difference (IV, Random, 95% CI)	1.87 [-6.72, 10.47]
4.80.3 psychological health	2	314	Mean Difference (IV, Random, 95% CI)	-4.66 [-12.26, 2.94]
4.80.4 social relationships	2	314	Mean Difference (IV, Random, 95% CI)	4.91 [-5.81, 15.63]
4.81 Quality of life: 2c. Specific - average endpoint score - short term (SF-36, high=good)	3		Mean Difference (IV, Random, 95% CI)	Subtotals only
4.81.1 physiological function	2	1255	Mean Difference (IV, Random, 95% CI)	-8.83 [-24.03, 6.37]
4.81.2 physical role	2	1255	Mean Difference (IV, Random, 95% CI)	-15.48 [-36.32, 5.35]
4.81.3 somatic pain	2	1255	Mean Difference (IV, Random, 95% CI)	-3.59 [-6.55, -0.63]
4.81.4 general health	2	1255	Mean Difference (IV, Random, 95% CI)	-2.93 [-5.31, -0.55]
4.81.5 life vitality	2	1255	Mean Difference (IV, Random, 95% CI)	-6.80 [-10.93, -2.68]
4.81.6 social function	2	1255	Mean Difference (IV, Random, 95% CI)	-5.70 [-12.20, 0.81]
4.81.7 emotional function	2	1255	Mean Difference (IV, Random, 95% CI)	-11.30 [-19.31, -3.30]
4.81.8 mental health	2	1255	Mean Difference (IV, Random, 95% CI)	-5.11 [-7.28, -2.94]
4.81.9 health change	1	100	Mean Difference (IV, Random, 95% CI)	-2.00 [-11.21, 7.21]
4.81.10 total score	1	100	Mean Difference (IV, Random, 95% CI)	-14.20 [-20.50, -7.90]
4.81.11 health - current	1	71	Mean Difference (IV, Random, 95% CI)	-0.02 [-0.57, 0.53]
4.82 Quality of life: 2d. Specific - average endpoint score - short term (QLS total, high score=good, skewed data)	0		Other data	No numeric data

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
4.83 Leaving the study early: 2. Any reason	33	8837	Risk Ratio (IV, Random, 95% CI)	1.25 [1.15, 1.35]
4.83.1 short term	18	4143	Risk Ratio (IV, Random, 95% CI)	1.27 [1.09, 1.48]
4.83.2 medium term	13	1589	Risk Ratio (IV, Random, 95% CI)	1.40 [1.16, 1.69]
4.83.3 long term	6	3105	Risk Ratio (IV, Random, 95% CI)	1.11 [1.03, 1.21]
4.84 Leaving the study early: 3a. Various reasons - short term	21		Risk Ratio (IV, Random, 95% CI)	Subtotals only
4.84.1 clinical deterioration - short term	5	227	Risk Ratio (IV, Random, 95% CI)	1.93 [0.76, 4.87]
4.84.2 death - short term	2	324	Risk Ratio (IV, Random, 95% CI)	0.31 [0.03, 2.90]
4.84.3 lack of efficacy - short term	13	3722	Risk Ratio (IV, Random, 95% CI)	1.29 [0.93, 1.80]
4.84.4 loss to follow-up - short term	7	3092	Risk Ratio (IV, Random, 95% CI)	1.22 [0.84, 1.77]
4.84.5 non-compliance - short term	6	2509	Risk Ratio (IV, Random, 95% CI)	1.23 [0.83, 1.83]
4.84.6 not eligible/eligible but unwilling to continue - short term	3	2694	Risk Ratio (IV, Random, 95% CI)	1.11 [0.93, 1.33]
4.84.7 patient's decision - short term	7	2514	Risk Ratio (IV, Random, 95% CI)	2.00 [1.40, 2.85]
4.84.8 physician decision - short term	4	461	Risk Ratio (IV, Random, 95% CI)	1.97 [0.71, 5.49]
4.84.9 protocol violation - short term	3	606	Risk Ratio (IV, Random, 95% CI)	0.44 [0.13, 1.51]
4.84.10 unspecified - short term	1	52	Risk Ratio (IV, Random, 95% CI)	1.54 [0.97, 2.46]
4.84.11 violent behavior - short term	1	35	Risk Ratio (IV, Random, 95% CI)	2.55 [0.11, 58.60]
4.84.12 withdrawal of informed consent - short term	4	529	Risk Ratio (IV, Random, 95% CI)	1.12 [0.46, 2.70]
4.84.13 personal conflict - short term	1	276	Risk Ratio (IV, Random, 95% CI)	0.78 [0.25, 2.40]
4.84.14 sponsor decision - short term	3	2127	Risk Ratio (IV, Random, 95% CI)	0.71 [0.18, 2.72]
4.84.15 withdrawal of informed consent - short term	4	529	Risk Ratio (IV, Random, 95% CI)	1.12 [0.46, 2.70]
4.85 Leaving the study early: 3b. Various reasons - medium term	6		Risk Ratio (IV, Random, 95% CI)	Subtotals only
4.85.1 diagnosis change - medium term	1	46	Risk Ratio (IV, Random, 95% CI)	4.76 [0.58, 39.40]
4.85.2 death - medium term	2	346	Risk Ratio (IV, Random, 95% CI)	2.86 [0.46, 17.88]
4.85.3 lack of efficacy - medium term	6	1109	Risk Ratio (IV, Random, 95% CI)	1.71 [0.92, 3.17]
4.85.4 loss to follow-up - medium term	2	346	Risk Ratio (IV, Random, 95% CI)	0.80 [0.35, 1.81]
4.85.5 non-compliance - medium term	1	208	Risk Ratio (IV, Random, 95% CI)	1.25 [0.64, 2.48]
4.85.6 patient's decision - medium term	3	546	Risk Ratio (IV, Random, 95% CI)	1.07 [0.65, 1.77]
4.85.7 physician decision - medium term	1	275	Risk Ratio (IV, Random, 95% CI)	0.86 [0.37, 2.01]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
4.85.8 protocol violation - medium term	2	346	Risk Ratio (IV, Random, 95% CI)	0.95 [0.31, 2.88]
4.85.9 unspecified - medium term	4	863	Risk Ratio (IV, Random, 95% CI)	0.76 [0.35, 1.67]
4.85.10 withdrawal, loss to follow up, patients decision - medium term	2	254	Risk Ratio (IV, Random, 95% CI)	1.61 [1.07, 2.42]
4.85.11 withdrawal of informed consent - medium term	2	517	Risk Ratio (IV, Random, 95% CI)	1.38 [1.02, 1.88]
4.86 Leaving the study early: 3c. Various reasons - long term	6		Risk Ratio (IV, Random, 95% CI)	Subtotals only
4.86.1 Loss to follow up - long term	1	256	Risk Ratio (IV, Random, 95% CI)	0.82 [0.34, 1.96]
4.86.2 lack of efficacy - long term	6	1379	Risk Ratio (IV, Random, 95% CI)	1.29 [0.98, 1.70]
4.86.3 patients decision - long term	2	300	Risk Ratio (IV, Random, 95% CI)	1.04 [0.59, 1.81]
4.86.4 non-compliance - long term	3	411	Risk Ratio (IV, Random, 95% CI)	1.38 [0.64, 2.96]
4.86.5 physician decision - long term	2	300	Risk Ratio (IV, Random, 95% CI)	1.59 [0.35, 7.28]
4.86.6 sponsor decision - long term	1	256	Risk Ratio (IV, Random, 95% CI)	0.54 [0.02, 13.23]
4.86.7 withdrawal, loss to follow up, patients decision - long term	1	111	Risk Ratio (IV, Random, 95% CI)	0.71 [0.31, 1.64]
4.87 Leaving study early: 4a. Average time until discontinuation - medium term (months)	2	201	Mean Difference (IV, Random, 95% CI)	-4.53 [-5.18, -3.88]
4.87.1 medium term	2	201	Mean Difference (IV, Random, 95% CI)	-4.53 [-5.18, -3.88]
4.88 Leaving study early: 4b. Average time until discontinuation - long term (months, skewed data)	0		Other data	No numeric data
4.89 Service use: 1a. Admission to hospital after randomisation	1		Risk Ratio (IV, Random, 95% CI)	Subtotals only
4.89.1 admission	1	153	Risk Ratio (IV, Random, 95% CI)	1.08 [0.58, 2.01]
4.90 Service use: 1b. Hospitalisation (skewed data)	1		Other data	No numeric data
4.90.1 prior psychiatric hospitalisation (number of patients)	1		Other data	No numeric data
4.90.2 median length of hospitalisation	1		Other data	No numeric data

Comparison 5

COMPARISON HALOPERIDOL vs OLANZAPINE: OLANZAPINE DOSE STUDY

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
5.1 Global state: Clinically important (short term)	6		Risk Ratio (IV, Random, 95% CI)	Subtotals only
5.1.1 any dose of olanzapine	3	2694	Risk Ratio (IV, Random, 95% CI)	0.84 [0.58, 1.20]
5.1.2 1mg olanzapine	1	169	Risk Ratio (IV, Random, 95% CI)	1.18 [0.83, 1.67]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size	
5.1.3 5mg olanzapine	2	302	Risk Ratio (IV, Random, 95% CI)	1.09 [0.84, 1.42]	
5.1.4 10 mg olanzapine	2	300	Risk Ratio (IV, Random, 95% CI)	0.96 [0.75, 1.23]	
5.1.5 15mg olanzapine	5	692	Risk Ratio (IV, Random, 95% CI)	0.86 [0.75, 0.98]	

History

Protocol first published: Issue 10, 2019

Contributions of authors

Khasan Ibragimov: protocol development, study selection, data extraction, study appraisal, statistical analyses, writing the report.

Augusto Llosa: protocol development, study selection, data extraction, study appraisal, statistical analyses, writing the report, guarantor of the review.

Gregory Keane: protocol development, study selection, study appraisal, writing the report, providing a clinical and policy perspective.

Cristina Carreño: protocol development, study selection, writing the report, providing a clinical and policy perspective.

Jie Cheng: study selection, data extraction, study appraisal.

Declarations of interest

Khasan Ibragimov: none known
Augusto Llosa: none known
Cristina Carreño: none known
Gregory Keane: none known
Jie Cheng: none known

Sources of support

Internal sources

- Médecins Sans Frontières (MSF), France
  This review was funded in full by the non-profit organization Médecins sans Frontières, through internal funds.

External sources

- None, Other
  There was not any external support on this review

Differences between protocol and review

The term "schizophrenia-like disorders" was renamed as "schizophrenia-spectrum disorders" in title and throughout the review.

The terms "effects" and "safety" were renamed as benefits and harms respectively throughout the review.

For binary outcomes, along with the calculation of relative risk (RR), we calculated the number needed to treat for an additional beneficial outcome (NNTB) and the number needed to treat for an additional harmful outcome (NNTH) taking into account the ease of the tools to understand for clinicians and readers.

The outcomes have been re-organized and re-named to conform with the names and details (e.g. scales, cut-off criteria) of outcomes identified during the review process.

Some prespecified summary of findings outcomes were replaced due to unavailability of findings

- Adverse effects or events: specific - incidence of clinically important metabolic effects; replaced with: Adverse effects or events: specific - metabolic - weight increase.
- Leaving study early due to discontinuation; replaced with: Leaving study early: adverse effects.

We added one additional subgroup analysis comparing equivalent therapeutic doses of Haloperidol and Olanzapine

Characteristics of studies

Characteristics of included studies [ordered by study ID]